Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen, Inc. | 1.46% | 243.82 | 1.3% | $795.90m | |
| IMMU | Immunomedics, Inc. | 0.07% | 85.36 | 11.0% | $697.18m | |
| MRNA | Moderna, Inc. | 6.60% | 69.47 | 0.0% | $666.49m | |
| NVAX | Novavax, Inc. | 10.86% | 113.56 | 96.5% | $629.01m | |
| ILMN | Illumina, Inc. | 4.74% | 299.89 | 3.5% | $582.79m | |
| GILD | Gilead Sciences, Inc. | 0.00% | 62.25 | 1.0% | $574.11m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.98% | 574.06 | 2.7% | $443.39m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 1.92% | 268.18 | 1.9% | $340.86m | |
| BIIB | Biogen, Inc. | 1.20% | 273.28 | 1.6% | $334.97m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 2.15% | 114.43 | 2.0% | $285.22m | |
| EXAS | EXACT Sciences Corp. | 3.60% | 97.70 | 20.7% | $257.29m | |
| SRNE | Sorrento Therapeutics, Inc. | 4.84% | 9.64 | 1.5% | $240.99m | |
| VXRT | Vaxart, Inc. | 7.40% | 7.40 | 0.0% | $213.88m | |
| SGEN | Seattle Genetics, Inc. | 3.08% | 184.95 | 6.0% | $212.14m | |
| MNTA | Momenta Pharmaceuticals, Inc. | 0.02% | 52.40 | 3.0% | $193.58m |
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.